TrialCancer science2018

Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation.

Takashi Kumagai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.